Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

被引:171
作者
Sinzinger, H [1 ]
O'Grady, J [1 ]
机构
[1] Wilhelm Auerswald Atherosclerosis Res Grp, Inst Diag & Treatment Atherosclerosis & Lipid Dis, A-1090 Vienna, Austria
关键词
creatine phosphokinase; familial hypercholesterolaemia; muscle pains; oxidation injury; professional athletes;
D O I
10.1111/j.1365-2125.2003.02044.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Muscular problems are the major group of side-effects during statin treatment. They are known to occur much more frequently during and after exercise. Methods and results For the last 8 years we have monitored 22 professional athletes in whom, because of familial hypercholesterolaemia, treatment with different statins was attempted. Only six out of the 22 finally tolerated at least one member of this family of drugs. In three of these six the first statin prescribed allowed training performance without any limitation. Changing the drug demonstrated that only two tolerated all the four or five statins examined (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin). Cerivastatin was not among the statins prescribed. Conclusions These findings indicate that in top sports performers only about 20% tolerate statin treatment without side-effects. Clinical decision making as to lipid lowering therapy thus becomes a critical issue in this small subgroup of patients.
引用
收藏
页码:525 / 528
页数:4
相关论文
共 14 条
[1]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[2]  
Gotto A M Jr, 1999, Circulation, V99, pE1
[3]  
Oguogho A, 1999, WIEN KLIN WOCHENSCHR, V111, P113
[4]   Rhabdomyolysis and HMG-CoA reductase inhibitors [J].
Omar, MA ;
Wilson, JP ;
Cox, TS .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) :1096-1107
[5]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[6]   Statin-associated myopathy with normal creatine kinase levels [J].
Phillips, PS ;
Haas, RH ;
Bannykh, S ;
Hathaway, S ;
Gray, NL ;
Kimura, BJ ;
Vladutiu, GD ;
England, JDF .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (07) :581-585
[7]  
Sinzinger H, 1999, ATHEROSCLEROSIS, V143, P459
[8]  
SINZINGER H, 1995, WIEN KLIN WOCHENSCHR, V107, P537
[9]   Oxidation injury in patients receiving HMG-CoA reductase inhibitors - Occurrence in patients without enzyme elevation or myopathy [J].
Sinzinger, H ;
Chehne, F ;
Lupattelli, G .
DRUG SAFETY, 2002, 25 (12) :877-883
[10]  
Sinzinger H, 2000, ATHEROSCLEROSIS, V149, P225